Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 6/20 | 0.59 |
| ▸ | CARM1 | Q86X55 | 6/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 6/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | HTR5A | P47898 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18129157 | 0.88 | MAP4K4 (0.58) | MAP4K4CARM1PRMT6HCRTR1HCRTR2 | |
| SCHEMBL18984688 | 0.86 | MAP4K4 (0.56) | MAP4K4CARM1PRMT6HCRTR1HCRTR2 | |
| SCHEMBL18129094 | 0.86 | MAP4K4 (0.56) | MAP4K4CARM1PRMT6HCRTR1HCRTR2 | |
| SCHEMBL375149 | 0.83 | MAP4K4 (0.58) | MAP4K4CARM1PRMT6 | |
| SCHEMBL18129078 | 0.80 | MAP4K4 (0.56) | MAP4K4CARM1PRMT6HCRTR1HCRTR2 | |
| SCHEMBL8081164 | 0.76 | ACHE (0.68) | CARM1PRMT6ACHEBACE1 | |
| SCHEMBL15587419 | 0.75 | ACHE (0.71) | MAP4K4CARM1PRMT6ACHEBACE1 | |
| SCHEMBL13321381 | 0.75 | VCP (0.49) | CARM1PRMT6 | |
| SCHEMBL18137750 | 0.75 | ACHE (0.52) | MAP4K4CARM1PRMT6ACHEBACE1 | |
| SCHEMBL15587664 | 0.75 | MAP4K4 (1.00) | MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | MAP4K4 662/4885CARM1 2613/4885PRMT6 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.